The global stomach cancer treatment market size is accounted at USD 6.08 billion in 2025 and is forecasted to hit around USD 17.60 billion by 2034, representing a healthy CAGR of 12.54% from 2025 to 2034. The Asia Pacific market size was estimated at USD 3.02 billion in 2024 and is expanding at a CAGR of 12.65% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Stomach Cancer Treatment Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Stomach Cancer Treatment Market, by Treatment Type, 2025-2034
8.1.1. Standard Chemotherapy
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Immunotherapy
8.1.3.1. Market Revenue and Forecast (2022-2034)
9.1. Stomach Cancer Treatment Market, by Disease Indication, 2025-2034
9.1.1. Gastric Cancer/Gastroesophageal Junction Cancer
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Gastrointestinal Stromal Tumors
9.1.2.1. Market Revenue and Forecast (2022-2034)
10.1. Stomach Cancer Treatment Market, by Route of Administration, 2025-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast (2022-2034)
11.1. Stomach Cancer Treatment Market, by Drug Class, 2025-2034
11.1.1. PD-1/PD-L1 Inhibitors
11.1.1.1. Market Revenue and Forecast (2022-2034)
11.1.2. HER2 Antagonists
11.1.2.1. Market Revenue and Forecast (2022-2034)
11.1.3. VEGFR Antagonists
11.1.3.1. Market Revenue and Forecast (2022-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2022-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.1.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.1.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.1.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.1.6.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.6.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.2.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.2.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.2.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.2.6.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.6.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.2.7.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.7.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.2.8.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.8.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.3.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.3.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.3.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.3.6.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.6.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.3.7.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.7.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.3.8.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.8.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.4.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.4.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.4.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.4.6.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.6.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.4.7.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.7.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.4.8.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.8.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.5.5.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.5.4. Market Revenue and Forecast, by Drug Class (2022-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Treatment Type (2022-2034)
12.5.6.2. Market Revenue and Forecast, by Disease Indication (2022-2034)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.6.4. Market Revenue and Forecast, by Drug Class (2022-2034)
13.1. Mylan N.V.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. CELLTRION INC.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Samsung Bioepis
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. F. Hoffmann-La Roche Ltd
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Eli Lilly and Company
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck & Co., Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Bristol-Myers Squibb Company
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample